Daiichi Sankyo Acquires Rights for Astellas' Three Therapies to Boost its Presence in Asia
Shots:
- Astellas to receive ~$88.3M as up front for its three products. Daiichi to get rights and obligations- including manufacturing and marketing approvals for Nasea (ramosetron)- Perdipine (nicardipine) and Oldeca (barnidipine) from Dec’2019
- The focus of the agreement is to strengthen Daiichi’s presence in Asia and to contribute to healthcare in Asia by acquiring two anti-hypertensive and anti-emetic therapies from Astellas
- Nasea is an antiemetic therapy- expected to have synergic effect with Daiichi’s Mirogabalin and the cancer therapies while Perdipine & Oldeca are anti-hypertensive therapies- expected to be utilized in combination with Daiichi’s cardiovascular products- Olmesartan and Edoxaban
Click here to read full press release/ article
Ref:Daiichi Sankyo | Image: Astellas
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com